Company intelligence / Profile preview

ERFwise

Cambridge, Massachusetts, United Statesrhodesia.com ↗

Ownership: Private
Development stage: Phase 1

Overview

No clinical results or pipeline information available. The only mention of the company comes from an executive’s resume, suggesting it may have been a consulting or advisory entity rather than a product-focused biotech.

Eric Fedyk lists experience at "ERFwise LLC" before joining major biopharma companies, indicating it was likely his own consultancy or small firm in the life sciences sector[1].
There are no public records of clinical programs, products, or technologies.
A similarly named entity ("Erfwise Traders") appears to be unrelated and involved in mineral trading rather than life sciences[2].

Industry: Consulting

Drug pipeline

3 assets

TAK-079

Phase 1

Indications: Multiple myeloma, Systemic lupus erythematosus

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ERFwise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERFwise.

Explore the full profile